237 related articles for article (PubMed ID: 30186836)
1. Commercial Scale Manufacturing of Allogeneic Cell Therapy.
Pigeau GM; Csaszar E; Dulgar-Tulloch A
Front Med (Lausanne); 2018; 5():233. PubMed ID: 30186836
[TBL] [Abstract][Full Text] [Related]
2. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
Abbasalizadeh S; Baharvand H
Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic cell therapy manufacturing: process development technologies and facility design options.
Abbasalizadeh S; Pakzad M; Cabral JMS; Baharvand H
Expert Opin Biol Ther; 2017 Oct; 17(10):1201-1219. PubMed ID: 28699788
[TBL] [Abstract][Full Text] [Related]
4. Enabling Allogeneic T Cell-Based Therapies: Scalable Stirred-Tank Bioreactor Mediated Manufacturing.
Gatla H; Uth N; Levinson Y; Navaei A; Sargent A; Ramaswamy S; Friedrich Ben-Nun I
Front Med Technol; 2022; 4():850565. PubMed ID: 35707712
[TBL] [Abstract][Full Text] [Related]
5. Challenges and Solutions for Commercial Scale Manufacturing of Allogeneic Pluripotent Stem Cell Products.
Lee B; Borys BS; Kallos MS; Rodrigues CAV; Silva TP; Cabral JMS
Bioengineering (Basel); 2020 Mar; 7(2):. PubMed ID: 32231012
[TBL] [Abstract][Full Text] [Related]
6. End-to-End Platform for Human Pluripotent Stem Cell Manufacturing.
Pandey PR; Tomney A; Woon MT; Uth N; Shafighi F; Ngabo I; Vallabhaneni H; Levinson Y; Abraham E; Friedrich Ben-Nun I
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877727
[TBL] [Abstract][Full Text] [Related]
7. Cell Culture Process Scale-Up Challenges for Commercial-Scale Manufacturing of Allogeneic Pluripotent Stem Cell Products.
Lee B; Jung S; Hashimura Y; Lee M; Borys BS; Dang T; Kallos MS; Rodrigues CAV; Silva TP; Cabral JMS
Bioengineering (Basel); 2022 Feb; 9(3):. PubMed ID: 35324781
[TBL] [Abstract][Full Text] [Related]
8. Platforms for Manufacturing Allogeneic, Autologous and iPSC Cell Therapy Products: An Industry Perspective.
Abraham E; Ahmadian BB; Holderness K; Levinson Y; McAfee E
Adv Biochem Eng Biotechnol; 2018; 165():323-350. PubMed ID: 28534167
[TBL] [Abstract][Full Text] [Related]
9. Automation of cellular therapy product manufacturing: results of a split validation comparing CD34 selection of peripheral blood stem cell apheresis product with a semi-manual vs. an automatic procedure.
Hümmer C; Poppe C; Bunos M; Stock B; Wingenfeld E; Huppert V; Stuth J; Reck K; Essl M; Seifried E; Bonig H
J Transl Med; 2016 Mar; 14():76. PubMed ID: 26983643
[TBL] [Abstract][Full Text] [Related]
10. How development and manufacturing will need to be structured--heads of development/manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Nepveux K; Sherlock JP; Futran M; Thien M; Krumme M
J Pharm Sci; 2015 Mar; 104(3):850-64. PubMed ID: 25630721
[TBL] [Abstract][Full Text] [Related]
11. Applications of Raman Spectroscopy in Biopharmaceutical Manufacturing: A Short Review.
Buckley K; Ryder AG
Appl Spectrosc; 2017 Jun; 71(6):1085-1116. PubMed ID: 28534676
[TBL] [Abstract][Full Text] [Related]
12. Scalable Expansion of Pluripotent Stem Cells.
Lavon N; Zimerman M; Itskovitz-Eldor J
Adv Biochem Eng Biotechnol; 2018; 163():23-37. PubMed ID: 29085956
[TBL] [Abstract][Full Text] [Related]
13. An Industry-Driven Roadmap for Manufacturing in Regenerative Medicine.
Hunsberger JG; Shupe T; Atala A
Stem Cells Transl Med; 2018 Aug; 7(8):564-568. PubMed ID: 30009571
[TBL] [Abstract][Full Text] [Related]
14. Towards Automated Manufacturing for Cell Therapies.
Smith D; Heathman TRJ; Klarer A; LeBlon C; Tada Y; Hampson B
Curr Hematol Malig Rep; 2019 Aug; 14(4):278-285. PubMed ID: 31254154
[TBL] [Abstract][Full Text] [Related]
15. Cell-Based Therapy Manufacturing in Stirred Suspension Bioreactor: Thoughts for cGMP Compliance.
Nath SC; Harper L; Rancourt DE
Front Bioeng Biotechnol; 2020; 8():599674. PubMed ID: 33324625
[TBL] [Abstract][Full Text] [Related]
16. How Development and Manufacturing Will Need to Be Structured-Heads of Development/Manufacturing May 20-21, 2014 Continuous Manufacturing Symposium.
Nepveux K; Sherlock JP; Futran M; Thien M; Krumme M
J Pharm Sci; 2015 Mar; 104(3):850-864. PubMed ID: 28756847
[TBL] [Abstract][Full Text] [Related]
17. Achieving continuous manufacturing: technologies and approaches for synthesis, workup, and isolation of drug substance. May 20-21, 2014 Continuous Manufacturing Symposium.
Baxendale IR; Braatz RD; Hodnett BK; Jensen KF; Johnson MD; Sharratt P; Sherlock JP; Florence AJ
J Pharm Sci; 2015 Mar; 104(3):781-91. PubMed ID: 25470351
[TBL] [Abstract][Full Text] [Related]
18. Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine.
Ratcliffe E; Thomas RJ; Williams DJ
Br Med Bull; 2011; 100():137-55. PubMed ID: 21852279
[TBL] [Abstract][Full Text] [Related]
19. Very-large-scale production of antibodies in plants: The biologization of manufacturing.
Buyel JF; Twyman RM; Fischer R
Biotechnol Adv; 2017 Jul; 35(4):458-465. PubMed ID: 28347720
[TBL] [Abstract][Full Text] [Related]
20. Manufacturing road map for tissue engineering and regenerative medicine technologies.
Hunsberger J; Harrysson O; Shirwaiker R; Starly B; Wysk R; Cohen P; Allickson J; Yoo J; Atala A
Stem Cells Transl Med; 2015 Feb; 4(2):130-5. PubMed ID: 25575525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
